2019
DOI: 10.1016/j.nmd.2019.06.316
|View full text |Cite
|
Sign up to set email alerts
|

O.33Subcutaneous immunoglobulin in myasthenia gravis: results of a North American open label study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…At a mean follow-up period of about 7 months, all had stable or improved MGFA status, significant improvement in MG-ADL, MG-QOL and the visual analogue scale (VAS) for patient satisfaction ( 36 ). The efficacy, safety and tolerability of SCIG in 22 seropositive MG patients was assessed in a multicentre North American open label trial ( 37 ). After a 10 week screening period with periodic IVIG treatments, stable patients were transitioned to weekly SCIG for 12 weeks.…”
Section: Subcutaneous Immunoglobulin (Scig)mentioning
confidence: 99%
See 1 more Smart Citation
“…At a mean follow-up period of about 7 months, all had stable or improved MGFA status, significant improvement in MG-ADL, MG-QOL and the visual analogue scale (VAS) for patient satisfaction ( 36 ). The efficacy, safety and tolerability of SCIG in 22 seropositive MG patients was assessed in a multicentre North American open label trial ( 37 ). After a 10 week screening period with periodic IVIG treatments, stable patients were transitioned to weekly SCIG for 12 weeks.…”
Section: Subcutaneous Immunoglobulin (Scig)mentioning
confidence: 99%
“…The study showed improved scores in the QMG, manual muscle testing (MMT), and MGC with high patient satisfaction and no serious adverse effects. The treatment success rate at 12 weeks was 85% (37,38). Thus SCIG offers a novel, efficacious and patient-friendly alternative to IVIG in maintenance therapy for MG, although it has not been tested for acute management of MG. Additionally, its corticosteroidsparing effects have not been established.…”
Section: Subcutaneous Immunoglobulin (Scig)mentioning
confidence: 99%